Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Open access

Abstract

Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such effects are mediated. A critical question is whether combination therapy targets and modulates the same T cell populations as monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled the response of T cell populations to monotherapy and combination anti–CTLA-4 plus anti–PD-1 therapy in syngeneic murine tumors and clinical samples. Most effects of monotherapies were additive in the context of combination therapy; however, multiple combination therapy-specific effects were observed. Highly phenotypically exhausted cluster of differentiation 8 (CD8) T cells expand in frequency following anti–PD-1 monotherapy but not combination therapy, while activated terminally differentiated effector CD8 T cells expand only following combination therapy. Combination therapy also led to further increased frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti–PD-1 monotherapy is not sufficient to do so. Mass cytometry analyses of peripheral blood from melanoma patients treated with immune checkpoint blockade therapies similarly revealed mostly additive effects on the frequencies of T cell subsets along with unique modulation of terminally differentiated effector CD8 T cells by combination ipilimumab plus nivolumab therapy. Together, these findings indicate that dual blockade of CTLA-4 and PD-1 therapy is sufficient to induce unique cellular responses compared with either monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1821218116

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Combination anti–CTLA-4 plus anti–PD-1 therapy differentially affects MC38 tumor-infiltrating T cell populations. (A) MC38 tumor volumes 13 d after tumor inoculation are displayed from mice treated with control, monotherapy, or combination anti–CTLA-4 plus anti–PD-1 therapy. (B) T cell frequency as a percentage of total MC38 tumor-infiltrating CD45+ cells. (C) Heat map of MC38 tumor-infiltrating T cell metaclusters displaying expression values of individual parameters normalized to the maximum mean value across metaclusters. (D) Relative frequency of CD8 T cell metaclusters. (E) Relative frequency of CD4 effector T cell metaclusters. (F) Relative frequency of Treg metaclusters. (G) Mean intensity of CTLA-4 of Treg metaclusters. Each data point reflects the mean intensity of the individual clusters associated with the metaclusters. Data are pooled from 3 biological replicate cohorts and are displayed on a per mouse basis. Mean and SD are displayed. *P < 0.05, 2-tailed t test with Welch’s correction. (See also SI Appendix, Fig. S1.)
Fig. 1. Combination anti–CTLA-4 plus anti–PD-1 therapy differentially affects MC38 tumor-infiltrating T cell populations. (A) MC38 tumor volumes 13 d after tumor inoculation are displayed from mice treated with control, monotherapy, or combination anti–CTLA-4 plus anti–PD-1 therapy. (B) T cell frequency as a percentage of total MC38 tumor-infiltrating CD45+ cells. (C) Heat map of MC38 tumor-infiltrating T cell metaclusters displaying expression values of individual parameters normalized to the maximum mean value across metaclusters. (D) Relative frequency of CD8 T cell metaclusters. (E) Relative frequency of CD4 effector T cell metaclusters. (F) Relative frequency of Treg metaclusters. (G) Mean intensity of CTLA-4 of Treg metaclusters. Each data point reflects the mean intensity of the individual clusters associated with the metaclusters. Data are pooled from 3 biological replicate cohorts and are displayed on a per mouse basis. Mean and SD are displayed. *P < 0.05, 2-tailed t test with Welch’s correction. (See also SI Appendix, Fig. S1.)CC BY-NC-ND · PubMed Central
Fig. 2. Correlative relationships between MC38 tumor growth and T cell subset frequency. (A) Relative frequency of denoted MC38 tumor-infiltrating T cell metaclusters plotted as a function of final tumor volume on day 13 postinoculation. Data from all treatment groups are displayed together. Data are pooled from the 3 biological replicate cohorts analyzed in Fig. 1 and are displayed on a per mouse basis. Data points are color-coded by treatment: control (blue), anti–CTLA-4 (red), anti–PD-1 (green), and combination (purple). n.s., not significant. (B) Relative frequency of Th1-like CD4 effector cells (metacluster 2) plotted as a function of final tumor volume. Data from all treatment groups are displayed together. (C) Relative frequency of regulatory T cells (metacluster 8) plotted as a function of final tumor volume. Data from all treatment groups are displayed together. (D) Frequency of IdU+ T cells is displayed for each MC38 tumor-infiltrating T cell metacluster on a per mouse basis. The mean and SD are displayed. Linear regression lines are displayed along with Spearman r and P values. (See also SI Appendix, Fig. S2.)
Fig. 2. Correlative relationships between MC38 tumor growth and T cell subset frequency. (A) Relative frequency of denoted MC38 tumor-infiltrating T cell metaclusters plotted as a function of final tumor volume on day 13 postinoculation. Data from all treatment groups are displayed together. Data are pooled from the 3 biological replicate cohorts analyzed in Fig. 1 and are displayed on a per mouse basis. Data points are color-coded by treatment: control (blue), anti–CTLA-4 (red), anti–PD-1 (green), and combination (purple). n.s., not significant. (B) Relative frequency of Th1-like CD4 effector cells (metacluster 2) plotted as a function of final tumor volume. Data from all treatment groups are displayed together. (C) Relative frequency of regulatory T cells (metacluster 8) plotted as a function of final tumor volume. Data from all treatment groups are displayed together. (D) Frequency of IdU+ T cells is displayed for each MC38 tumor-infiltrating T cell metacluster on a per mouse basis. The mean and SD are displayed. Linear regression lines are displayed along with Spearman r and P values. (See also SI Appendix, Fig. S2.)CC BY-NC-ND · PubMed Central
Fig. 3. Mass cytometry analysis of peripheral blood from patients treated with checkpoint blockade reveals treatment-specific effects. (A) Frequency of Ki-67+ cells within PD-1− and PD-1+ fractions of CD8 T cells in peripheral blood from patients treated with checkpoint blockade therapies (anti–CTLA-4, ipilimumab [Ipi], anti–PD-1 monotherapy, and ipilimumab plus nivolumab [Ipi + Nivo]) and normal donors is displayed. *P < 0.05, 1-way ANOVA with Sidak’s multiple testing correction. n.s., not significant. (B) tSNE plot of T cells from peripheral blood from patients treated with checkpoint blockade therapies. The plot is color-coded by treatment. Equal numbers of events per treatment group are displayed. (C) tSNE plots of T cells from peripheral blood overlaid with the expression levels of CD4, CD8, and TBET as heat maps. (D) Frequency of CD8 T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05 Tukey’s 2-way ANOVA with multiple testing correction. The mean and SD are displayed for each frequency plot. ND, normal donor. (E) Frequency of CD4 effector T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05, Tukey’s 2-way ANOVA with multiple testing correction. (See also SI Appendix, Figs. S3 and S4.)
Fig. 3. Mass cytometry analysis of peripheral blood from patients treated with checkpoint blockade reveals treatment-specific effects. (A) Frequency of Ki-67+ cells within PD-1− and PD-1+ fractions of CD8 T cells in peripheral blood from patients treated with checkpoint blockade therapies (anti–CTLA-4, ipilimumab [Ipi], anti–PD-1 monotherapy, and ipilimumab plus nivolumab [Ipi + Nivo]) and normal donors is displayed. *P < 0.05, 1-way ANOVA with Sidak’s multiple testing correction. n.s., not significant. (B) tSNE plot of T cells from peripheral blood from patients treated with checkpoint blockade therapies. The plot is color-coded by treatment. Equal numbers of events per treatment group are displayed. (C) tSNE plots of T cells from peripheral blood overlaid with the expression levels of CD4, CD8, and TBET as heat maps. (D) Frequency of CD8 T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05 Tukey’s 2-way ANOVA with multiple testing correction. The mean and SD are displayed for each frequency plot. ND, normal donor. (E) Frequency of CD4 effector T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05, Tukey’s 2-way ANOVA with multiple testing correction. (See also SI Appendix, Figs. S3 and S4.)CC BY-NC-ND · PubMed Central
Fig. 4. Specific subsets of phenotypically defined T cell populations within the TME are detectable in peripheral blood of treatment-naive patients. (A) Heat map of T cell metaclusters identified across matched human lung tumors, normal adjacent lung, and peripheral blood. Expression values of individual parameters are normalized to the maximum mean value across metaclusters. (B) Mean frequency of T cell metaclusters in blood plotted as a function of their respective frequencies in tumor tissue. Interpatient variability is displayed within each tissue as the SE. Metacluster clusters are annotated. (C) Mean frequency of T cell metaclusters in normal adjacent lung plotted as a function of their respective frequencies in tumor tissue. (See also SI Appendix, Fig. S5.)
Fig. 4. Specific subsets of phenotypically defined T cell populations within the TME are detectable in peripheral blood of treatment-naive patients. (A) Heat map of T cell metaclusters identified across matched human lung tumors, normal adjacent lung, and peripheral blood. Expression values of individual parameters are normalized to the maximum mean value across metaclusters. (B) Mean frequency of T cell metaclusters in blood plotted as a function of their respective frequencies in tumor tissue. Interpatient variability is displayed within each tissue as the SE. Metacluster clusters are annotated. (C) Mean frequency of T cell metaclusters in normal adjacent lung plotted as a function of their respective frequencies in tumor tissue. (See also SI Appendix, Fig. S5.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. M. Postow ., “Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma” in 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One, P. J. Romero, Ed. (Journal for ImmunoTherapy of Cancer, 2017), vol. 5, p. 86.

Cited by

See all 362

Metadata

Authors
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., & Allison, J. P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Columbia University (US)
  • Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065;
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Allison, James P.
Venue
Proceedings of the National Academy of Sciences
Published
2019-10-21
Volume
116
Issue
45
Pages
22699-22709
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2981443129
Cited by
359
References
55
Citations by year
2026: 38 · 2025: 42 · 2024: 47 · 2023: 52 · 2022: 69 · 2021: 63 · 2020: 47 · 2019: 1
FWCI
18.88
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • HHS | NIH | National Cancer Institute (P30CA16672)
  • Cancer Prevention and Research Institute of Texas (R1203)
  • National Health and Medical Research Council of Australia (#1148680)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint blockade, anti-CTLA-4, anti-PD-1, combination immunotherapy, T cell exhaustion, CD8+ T cells, melanoma, ipilimumab, nivolumab, mass cytometry, T cell subsets
MeSH terms
Animals, Immunotherapy, Neoplasms, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. https://app.cochat.ai/papers/10.1073/pnas.1821218116
The paper
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., & Allison, J. P. (2019). Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1821218116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.